Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Incidence of infusion reactions to intravenous golimumab: results from a prospective, real-world community registry.

Faraawi R, Chow A, Khraishi M, Haaland D, Nantel F, Osborne B.

Clin Exp Rheumatol. 2019 Nov 18. [Epub ahead of print] No abstract available.

PMID:
31820720
2.

Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.

Khraishi M, Millson B, Woolcott J, Jones H, Marshall L, Ruperto N.

Pediatr Rheumatol Online J. 2019 Sep 10;17(1):64. doi: 10.1186/s12969-019-0358-x.

3.

Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study.

Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant MJ, Woolcott J, Jones H, Curiale C.

Curr Med Res Opin. 2019 Nov;35(11):2025-2033. doi: 10.1080/03007995.2019.1636543. Epub 2019 Jul 10.

PMID:
31237785
4.

Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.

Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, Haaland D, Elmoufti S, Staelens F, Bogatyreva I, Syrotuik J, Shaikh S.

Ther Adv Musculoskelet Dis. 2019 Mar 5;11:1759720X19831151. doi: 10.1177/1759720X19831151. eCollection 2019.

5.

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study.

Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M.

Rheumatol Ther. 2018 Dec;5(2):551-565. doi: 10.1007/s40744-018-0130-6. Epub 2018 Oct 28.

6.

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database.

Baer PA, Aumais G, Ewara EM, Khraishi M, Marrache AM, Panaccione R, Wade JP, Marshall JK.

Patient Prefer Adherence. 2018 Sep 18;12:1805-1814. doi: 10.2147/PPA.S171363. eCollection 2018. Erratum in: Patient Prefer Adherence. 2018 Oct 18;12:2221.

7.

Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data.

Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant MJ, Charland K, Woolcott J, Jones H.

Clin Rheumatol. 2018 Sep;37(9):2351-2360. doi: 10.1007/s10067-018-4141-z. Epub 2018 May 16.

PMID:
29766376
8.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

9.

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment.

Bessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M, Isaila M, Collier D.

Rheumatol Ther. 2017 Dec;4(2):391-404. doi: 10.1007/s40744-017-0079-x. Epub 2017 Sep 12.

10.

Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice.

Gladman DD, Poulin Y, Adams K, Bourcier M, Barac S, Barber K, Chandran V, Dutz J, Flanagan C, Gooderham MJ, Gulliver WP, Ho VC, Hong CH, Karsh J, Khraishi MM, Lynde CW, Papp KA, Rahman P, Rohekar S, Rosen CF, Russell AS, Vender RB, Yeung J, Ziouzina O, Zummer M.

J Rheumatol. 2017 Apr;44(4):519-534. doi: 10.3899/jrheum.161473.

PMID:
28604347
11.

Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.

Rahman P, Choquette D, Bensen WG, Khraishi M, Chow A, Zummer M, Shaikh S, Sheriff M, Dixit S, Sholter D, Psaradellis E, Sampalis JS, Letourneau V, Lehman AJ, Nantel F, Rampakakis E, Otawa S, Shawi M.

BMJ Open. 2016 Apr 5;6(4):e009661. doi: 10.1136/bmjopen-2015-009661.

12.

Biosimilars: A Multidisciplinary Perspective.

Khraishi M, Stead D, Lukas M, Scotte F, Schmid H.

Clin Ther. 2016 May;38(5):1238-49. doi: 10.1016/j.clinthera.2016.02.023. Epub 2016 Mar 14.

13.

CanVasc recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides - Executive summary.

McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler S, Cabral DA, Carette S, Cox GP, Dhindsa N, Dipchand C, Fifi-Mah A, Goulet M, Khalidi N, Khraishi MM, Liang P, Milman N, Pineau CA, Reich H, Samadi N, Shojania K, Taylor-Gjevre R, Towheed TE, Trudeau J, Walsh M, Yacyshyn E, Pagnoux C; Canadian Vasculitis research network (CanVasc).

Can J Kidney Health Dis. 2015 Nov 9;2:43. doi: 10.1186/s40697-015-0078-1. eCollection 2015. Review.

14.

CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides.

McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler SM, Cabral DA, Carette S, Cox GP, Dhindsa N, Dipchand CS, Fifi-Mah A, Goulet M, Khalidi N, Khraishi MM, Liang P, Milman N, Pineau CA, Reich HN, Samadi N, Shojania K, Taylor-Gjevre R, Towheed TE, Trudeau J, Walsh M, Yacyshyn E, Pagnoux C; Canadian Vasculitis Research Network.

J Rheumatol. 2016 Jan;43(1):97-120. doi: 10.3899/jrheum.150376. Epub 2015 Nov 1. Review.

PMID:
26523024
15.

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.

Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D.

RMD Open. 2015 Jun 25;1(1):e000119. doi: 10.1136/rmdopen-2015-000119. eCollection 2015.

16.

Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire.

Famorca L, Twilt M, Barra L, Bakowsky V, Benseler S, Cabral D, Carette S, Dhindsa N, Fifi-Mah A, Goulet M, Khalidi N, Khraishi M, McGeoch L, Milman N, Pineau C, Shojania K, Taylor-Gjevre R, Towheed T, Trudeau J, Yacyshyn E, Liang P, Pagnoux C; Canadian Vasculitis network (CanVasc).

Open Rheumatol J. 2015 Apr 14;9:16-20. doi: 10.2174/18743129014090100016. eCollection 2015.

17.

Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians.

Khraishi MM.

Ther Adv Musculoskelet Dis. 2014 Oct;6(5):159-68. doi: 10.1177/1759720X14551567. Review.

18.

Prevalence of cardiovascular risk factors in patients with psoriatic arthritis.

Khraishi M, Aslanov R, Rampakakis E, Pollock C, Sampalis JS.

Clin Rheumatol. 2014;33(10):1495-500. doi: 10.1007/s10067-014-2743-7. Epub 2014 Jul 18.

PMID:
25034080
19.

Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics.

Mease PJ, Gladman DD, Helliwell P, Khraishi MM, Fuiman J, Bananis E, Alvarez D.

J Am Acad Dermatol. 2014 Oct;71(4):649-55. doi: 10.1016/j.jaad.2014.05.010. Epub 2014 Jun 25.

PMID:
24974240
20.

Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.

Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, Kelsall JT, Lehman AJ, Shawi M, Khalil H, Nantel F, Rampakakis E, Sampalis JS, Otawa S.

Arthritis Care Res (Hoboken). 2014 Aug;66(8):1142-51. doi: 10.1002/acr.22290.

21.

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D.

J Am Acad Dermatol. 2013 Nov;69(5):729-735. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.

PMID:
23981683
22.

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D.

Ann Rheum Dis. 2014 Jan;73(1):48-55. doi: 10.1136/annrheumdis-2013-203696. Epub 2013 Aug 13.

23.

Dermatology screening tools: project update from the GRAPPA 2012 annual meeting.

Gladman DD, Helliwell PS, Khraishi M, Callis Duffin K, Mease PJ.

J Rheumatol. 2013 Aug;40(8):1425-7. doi: 10.3899/jrheum.130455.

PMID:
23908538
24.

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, Van Vollenhoven R.

J Rheumatol. 2013 Jun;40(6):768-80. doi: 10.3899/jrheum.120687. Epub 2013 Mar 1.

PMID:
23457383
25.

Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort.

Tavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazovskis J, Blocka KL, Bell MJ, Lacaille D, Hitchon CA, Fitzgerald AA, Fidler WK, Bookman AA, Henderson JM, Mosher DP, Sholter DE, Khraishi M, Haraoui B, Chen H, Li X, Laupacis A, Boire G, Tomlinson G, Bombardier C.

J Rheumatol. 2012 Nov;39(11):2088-97. doi: 10.3899/jrheum.120100. Epub 2012 Aug 15.

PMID:
22896027
26.

Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.

Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Légaré J, Mosher DP, Pencharz J, Pope JE, Thomson J, Thorne C, Zummer M, Gardam MA, Askling J, Bykerk V; Canadian Rheumatology Association.

J Rheumatol. 2012 Aug;39(8):1583-602. doi: 10.3899/jrheum.120165. Epub 2012 Jun 15.

27.

High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice.

Khraishi M, Chouela E, Bejar M, Landells I, Hewhook T, Rampakakis E, Sampalis JS, Abouchehade K.

J Cutan Med Surg. 2012 Mar-Apr;16(2):122-7.

PMID:
22513065
28.

Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.

Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Légaré J, Mosher DP, Pencharz J, Pope JE, Thomson J, Thorne C, Zummer M, Bombardier C; Canadian Rheumatology Association.

J Rheumatol. 2012 Aug;39(8):1559-82. doi: 10.3899/jrheum.110207. Epub 2011 Sep 15.

29.

Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort.

Tavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazovskis J, Blocka KL, Bell MJ, Lacaille D, Hitchon CA, Fitzgerald AA, Fidler WK, Bookman AA, Henderson JM, Mosher DP, Sholter DE, Khraishi M, Haraoui B, Chen H, Li X, Laupacis A, Boire G, Tomlinson G, Bombardier C.

J Rheumatol. 2011 Nov;38(11):2342-5. doi: 10.3899/jrheum.110249. Epub 2011 Sep 1.

PMID:
21885485
30.

Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.

Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M.

J Rheumatol. 2011 Jul;38(7):1355-62. doi: 10.3899/jrheum.100698. Epub 2011 May 15.

31.
32.

Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts.

Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS.

Clin Rheumatol. 2011 Jul;30(7):877-85. doi: 10.1007/s10067-011-1692-7. Epub 2011 Feb 2.

PMID:
21287359
33.

Safety profile of abatacept in rheumatoid arthritis: a review.

Khraishi M, Russell A, Olszynski WP.

Clin Ther. 2010 Oct;32(11):1855-70. doi: 10.1016/j.clinthera.2010.10.011. Review.

PMID:
21095481
34.

Is the Canadian healthcare system neglecting a significant proportion of the rheumatoid arthritis population?

Haraoui B, El-Gabalawy H, Khraishi M, Thorne C.

J Rheumatol. 2009 Dec;36(12):2841; author reply 2842. doi: 10.3899/jrheum.090321. No abstract available.

PMID:
19966195
35.

Comparative overview of safety of the biologics in rheumatoid arthritis.

Khraishi M.

J Rheumatol Suppl. 2009 Jun;82:25-32. doi: 10.3899/jrheum.090128. Review.

PMID:
19509327
36.

The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis.

Landells I, MacCallum C, Khraishi M.

Skin Therapy Lett. 2008 May;13(4):4-7.

37.

A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.

Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, Bell M, Hudson M, Mathieu JP, Taillefer S, Jones N, Docherty P, Khraishi M, Markland J, Pope J, Robinson D, Smith D, Sutton E.

Clin Rheumatol. 2008 Jan;27(1):77-83. Epub 2007 Jun 15.

PMID:
17570008
38.
39.

CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis.

Rahman P, Bartlett S, Siannis F, Pellett FJ, Farewell VT, Peddle L, Schentag CT, Alderdice CA, Hamilton S, Khraishi M, Tobin Y, Hefferton D, Gladman DD.

Am J Hum Genet. 2003 Sep;73(3):677-81. Epub 2003 Jul 23.

40.

Probing for genes in seronegative spondyloarthropathy.

Stone M, Khraishi MM, Rahman P.

Curr Rheumatol Rep. 2000 Aug;2(4):306-10. Review.

PMID:
11123075
41.

Systemic sclerosis (scleroderma) in two iron ore mines.

Martin JR, Griffin M, Moore E, Lochead JA, Edwards AC, Williams J, Khraishi MM.

Occup Med (Lond). 1999 Apr;49(3):161-9.

PMID:
10451597
42.

The role of anti-malarials in rheumatoid arthritis--the American experience.

Khraishi MM, Singh G.

Lupus. 1996 Jun;5 Suppl 1:S41-4. Review.

PMID:
8803910
43.

Primary angiitis of the CNS diagnosed by angiography.

Abu-Shakra M, Khraishi M, Grosman H, Lewtas J, Cividino A, Keystone EC.

Q J Med. 1994 Jun;87(6):351-8.

PMID:
8041867
44.

Lymphadenopathy, oligoclonal T cell receptor rearrangement and systemic lupus erythematosus.

Khraishi M, Reis M, Berinstein N, Rubin L.

J Rheumatol. 1992 Dec;19(12):1966-9.

PMID:
1294749
45.

A patient with Werner's syndrome and osteosarcoma presenting as scleroderma.

Khraishi M, Howard B, Little H.

J Rheumatol. 1992 May;19(5):810-3.

PMID:
1613716
46.

HLA antigens in North American patients with Takayasu arteritis.

Khraishi MM, Gladman DD, Dagenais P, Fam AG, Keystone EC.

Arthritis Rheum. 1992 May;35(5):573-5.

PMID:
1349480
47.

Inclusion body myositis in association with vitamin B12 deficiency and Sjögren's syndrome.

Khraishi MM, Jay V, Keystone EC.

J Rheumatol. 1992 Feb;19(2):306-9.

PMID:
1629834
48.

Treatment of fulminant adult Still's disease with intravenous pulse methylprednisolone therapy.

Khraishi M, Fam AG.

J Rheumatol. 1991 Jul;18(7):1088-90. Review.

PMID:
1920313
49.

Paget's pseudosarcoma.

Khraishi M, Howard B, Fam AG.

Arthritis Rheum. 1991 Feb;34(2):241-3. No abstract available.

PMID:
1994924

Supplemental Content

Loading ...
Support Center